：能源与ESG周报 ...

：印度研究总结 ...

Equity – Asia Research 日本老龄化下医药市场机遇 Opportunities in the Pharmaceutical Market Amidst Japan's Aging Society 孟科含 Kehan Meng kh.meng@htisec.com 孙旭东 Xudong Sun xd.sun@htisec.com 2024年6月12日 本研究报告由海通国际分销，海通国际是由海通国际研究有限公司，海通证券印度私人有限公司，海通国际株式会社和海通国际证券集团其他各成员单位的证券 研究团队所组成的全球品牌，海通国际证券集团各成员分别在其许可的司法管辖区内从事证券活动。关于海通国际的分析师证明，重要披露声明和免责声明，请 参阅附录。(PleaseseeappendixforEnglishtranslationofthedisclaimer) 东证医药股市值集中，大药企主导 ...

Financial Data and Key Metrics - The Tokyo Stock Exchange's pharmaceutical sector has a market capitalization of $4,247 billion, accounting for 6.5% of the total market capitalization [3] - The A-share pharmaceutical market has a total market capitalization of $847.7 billion, accounting for 7.1% of the total A-share market capitalization, slightly higher than the Tokyo Stock Exchange [3] - The total market capitalization of the Tokyo Stock Exchange is $6.5 trillion [4] Business Line Data and Key Metrics - The Japanese pharmaceutical market is highly concentrated, with major pharmaceutical companies dominating. The top 10 companies account for 74.8% of the market capitalization [6] - In contrast, the Chinese pharmaceutical market is less concentrated, with the top 10 companies accounting for only 19.5% of the market capitalization [6] - The market capitalization of Japanese pharmaceutical companies has increased significantly over the years, with companies like Daiichi Sankyo and Takeda Pharmaceutical showing substantial growth [6] Market Data and Key Metrics - Japan's aging society presents significant opportunities for the pharmaceutical market. The proportion of the population aged 65 and above is 29%, compared to 15% in China [9] - Japan entered a moderately aging society in 1994, while China entered this phase in 2021, indicating a similar trajectory to Japan's 1990s [8] - The healthcare expenditure growth rate in Japan during its aging period (70s-90s) was 10.2%, significantly higher than the GDP growth rate of 7.5% [10] Company Strategy and Industry Competition - Japanese pharmaceutical companies have successfully expanded overseas, leveraging partnerships with multinational corporations (MNCs) and technological advancements. For example, Takeda Pharmaceutical's overseas revenue accounted for 87% of its total revenue in 2022 [15] - Japanese medical device companies, such as Terumo, have also seen significant growth through overseas expansion, with overseas revenue accounting for 75% of total revenue in 2022 [15] - The Chinese pharmaceutical market, while larger in size, has not yet seen companies of the same scale as Japanese pharmaceutical giants. However, the market is expected to grow significantly due to the aging population [25] Management Commentary on Operating Environment and Future Prospects - The aging population in Japan has driven demand for healthcare products and services, particularly in areas such as mental health, respiratory diseases, and cancer [18] - Companies like Hisamitsu Pharmaceutical have benefited from the growing demand for pain relief products, driven by an aging workforce and increased prevalence of chronic pain [18] - The Japanese government has implemented policies to control healthcare costs, but the proportion of healthcare expenditure to GDP continues to rise [10] Other Important Information - The Japanese pharmaceutical market is expected to remain resilient and show growth potential during the moderate aging period [7] - The Chinese pharmaceutical market is expected to benefit from the aging population, with healthcare expenditure growing at a rate of 24.7% from 2000 to 2021, compared to a GDP growth rate of 14.2% [10] - The Chinese market offers significant opportunities for pharmaceutical companies due to its large population and growing healthcare needs, with the market size being twice that of Japan [25] Summary of Q&A Session - No specific Q&A session content was provided in the documents

论坛 b197534b9f78f1b4ae366818a9df0ca3cc3e965b 名创优品——海外市场2024年上半年跟踪 2024年6月6日 核心洞察 专家 前任名创优品股份有限公司区域经理 > 印尼：þ名ÿþ创ÿ优品2024年上半年新开店 主持人 Donn Hu (DH), 高临行业分析师 约53家，已经突破300家，增长空间约 500家。老店改大店遇到阻力，部分老 议程 店店效提升不及预期，IP主题店 400-500平米以上，月店效150万元/ > 名创优品（NYSE: MNSO）——海外市场2024年上 月。名创优品在印尼市场定位轻奢， 半年发展态势及驱动力 街店模型还未跑通。 > IP主题店的运营效率和扩张、店效利润提升空间、 > 美国：þ名ÿþ创ÿ优品2024年上半年新开店 产品组合变化、快闪店拓展策略 约41家，预计中长期同店增长约 > 北美、拉美、新兴市场、欧洲市场的拓店进程、竞 10%，门店净利率目前低于20%，预 争趋势 计未来最高提升至30%。预计2025年 开始实现与印尼市场同样的经营模 ...

宏华集团（0196.HK）海洋工程装备生产基地投资者开放日20240606 宏华海洋油气装备（江苏）有限公司是宏华集团附属公司，其位于长江入海口的江苏省启东海工船 舶工业园，是海洋工程装备领域集设计、建造、调试为一体的高新技术企业，厂区占地约140万平方 米，岸线长1800米，重型组块建造车间11万平米，拥有万吨龙门吊"宏海号"、舾装码头、材料码 头、港池等一系列配套设施，总体规划和布局合理，工艺流程高效，是母公司东方宏华海洋工程装备 的重要建造基地。 公司业务范围覆盖海上风电桩基钢构、升压站、海洋油气模块、船舶分/总段、容器等大型钢结构 建造加工，同时具备中小型工程船舶整体建造能力，在大型风电导管架细分市场占有率名列前茅。 核心亮点： 1.区位优势：宏华海洋基地位于长江入海口北岸，距离上海浦东国际机场仅 100 公里，拥有长达 1800 米的黄金海岸线，一期已投入使用的岸线长度 800 米，主航道自然水深处于 5.5 米至 8 米之 间，码头侧设计深度在 8 米左右。岸上还配备了 60 吨及 45 吨的岸吊各 1 台，对大型产品的运输 和服务具备显著的交通便利优势和成本优势。并且，这些资源还能作为未来海外业 ...

Financial Data and Key Metrics Changes - The company reported a compound annual growth rate (CAGR) of over 50% in R&D expenses from 2020 to 2023, with R&D expenses reaching 636 million in 2023, a 27.2% increase from 2022 [15][16] - R&D investment accounted for 50.6% of total revenue, the highest among vaccine companies with commercialized products [16] Business Line Data and Key Metrics Changes - The company has eight commercialized vaccine products and 21 in development, with plans to increase the number of commercialized products to eight within the next one to two years [6][14] - The main products include hepatitis B vaccines, which account for 80% of revenue from the second category of vaccines, and rabies vaccines, which contribute 30% to total sales [23][18] Market Data and Key Metrics Changes - The company holds a market share of 20% in the rabies vaccine sector, maintaining the second position in the market [23] - The adult hepatitis B vaccine market is expected to grow significantly, driven by government initiatives targeting the screening and vaccination of the adult population [19][22] Company Strategy and Development Direction - The company aims to become a global leader in the vaccine industry, focusing on continuous innovation and development of major vaccine products [52][54] - The strategy includes leveraging advanced technology platforms, such as the MR technology platform, to develop new vaccines and enhance production capabilities [30][54] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the future clinical progress of the company, highlighting the submission of multiple vaccine applications to regulatory authorities [13][14] - The company anticipates significant market opportunities, estimating a potential market size of 400 billion for its products, which could lead to explosive growth [53][54] Other Important Information - The company is recognized as the largest hepatitis B vaccine manufacturer globally and the second-largest rabies vaccine manufacturer [53] - It has established four licensed vaccine production facilities and three research institutes, positioning itself as a key player in the vaccine industry [53] Q&A Session Summary Question: What is the company's outlook on the adult hepatitis B vaccine market? - Management indicated that the adult hepatitis B vaccine market is expected to open up significantly due to government initiatives aimed at screening and vaccination, with a focus on the 86 million individuals carrying the hepatitis B virus in China [19][22] Question: How does the company plan to enhance its product pipeline? - The company plans to submit applications for three major vaccine products this year, with all production facilities completed and ready for commercialization upon regulatory approval [14][15]

Financial Data and Key Metrics Changes - The company has not disclosed specific financial data or key metrics changes in the provided content [1][2] Business Line Data and Key Metrics Changes - The cell therapy business has shown significant clinical results, with 94% of patients achieving complete remission after treatment with the product Conviction, indicating strong potential for future Phase III trials [3][4] - In a subgroup analysis for second-line patients, the risk of disease progression was reduced by 65% compared to standard therapy, with a 73% reduction in high-risk patients [6][7] Market Data and Key Metrics Changes - The company has not provided specific market data or key metrics changes in the provided content [1][2] Company Strategy and Development Direction and Industry Competition - The company aims to expand its global footprint and enhance product and service competitiveness, focusing on research and development to create more valuable products for customers [19][20] - The management emphasizes compliance and providing high-quality products to meet unmet clinical needs as key strategies for overcoming challenges in the international market [28] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the external environment's uncertainties but expresses confidence in the company's ability to adapt and continue growth [17][18] - The company is actively increasing resources in government relations, public relations, and legal compliance to address inquiries from the U.S. House of Representatives [15][16] Other Important Information - The company has over 300 patents and more than 900 patents pending, highlighting its commitment to intellectual property [12] - The company has established production facilities in various locations, including mainland China, Singapore, and New Jersey, to better serve global customers [14] Q&A Session Summary Question: Will there be adjustments or upgrades to the business model due to external uncertainties? - Management reiterated its commitment to expanding global operations and enhancing product competitiveness without any changes to its long-term development strategy [18][19] Question: Has there been any discussion regarding the stock prices of subsidiaries and potential buybacks? - Management noted that both cell therapy and non-cell therapy businesses are experiencing rapid growth and significant potential profitability, which is not fully reflected in current market prices [20][21] Question: What is the current status of the collaboration with Legend Biotech and any potential impacts on synergies? - Management confirmed that all business operations and collaborations are proceeding normally without any changes [22][23] Question: What are the key considerations for clients in different business segments? - Management stated that clients prioritize delivery quality, speed, and price, which remain consistent across all service offerings [25][26]

Financial Data and Key Indicator Changes - The company's revenue for 2023 was $3,606 million, a decrease of 11.9% year-over-year from $4,095 million in 2022. Projected revenues for 2024, 2025, and 2026 are $4,265 million, $4,494 million, and $4,708 million respectively, indicating a recovery and growth trend [8][12] - Net profit for 2023 was $278 million, a slight increase of 5.3% from $264 million in 2022. Forecasted net profits for the next three years are $343 million, $377 million, and $445 million, reflecting a positive growth outlook [8][12] - The gross margin improved from 19.7% in 2022 to 24.3% in 2023, with expectations to maintain around 24.2% to 27.3% in the following years [8][12] Business Line Data and Key Indicator Changes - Copper production from the company's own mines increased significantly from 99,000 tons in 2020 to 169,000 tons in 2023, with a compound annual growth rate of 20%. Future projects are expected to further enhance production capacity [5][8] - The company’s copper smelting production has steadily increased, with 2023 outputs of 286,000 tons of crude copper, 142,000 tons of anode copper, and 955,000 tons of sulfuric acid, marking growth rates of 11%, 23%, and 20% respectively since 2020 [8][9] Market Data and Key Indicator Changes - The company is focusing on expanding its copper smelting capacity in Africa, with key smelting facilities including Qianbixi and Luallaba. The production from these facilities is expected to contribute significantly to revenue growth [7][9] - The company’s market positioning is strengthened by its vertical integration in the copper industry, which is expected to enhance profitability as self-sufficient production increases [7][9] Company Strategy and Development Direction - The company aims to expand its own copper mining capacity and enhance its smelting operations in Africa, which aligns with its strategy to become a leading player in the copper and cobalt resource sector [5][7] - Future projects include the Baruba open-pit mine and the revival of the Gangbof West ore body, which are expected to significantly increase production capacity [5][8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery in copper prices and the expected increase in production capacity, which should improve profitability in the coming years [7][9] - The company is aware of potential risks, including slower-than-expected expansion and rising raw material costs, but remains confident in its strategic direction and market demand [7][9] Other Important Information - The company has a projected EPS of $0.09, $0.10, and $0.11 for 2024, 2025, and 2026 respectively, with a target PE ratio of 12-13 times for 2024, translating to a fair value range of HKD 8.10-8.78 per share [7][8] - The company maintains a strong balance sheet with a projected debt-to-equity ratio decreasing from 34.9% in 2023 to 28.07% in 2026, indicating improved financial stability [12] Q&A Session Summary Question: What are the expectations for copper production in the coming years? - The company anticipates its own copper production to reach 169,000 tons in 2024, with further increases expected in subsequent years as new projects come online [5][8] Question: How does the company plan to mitigate risks associated with raw material costs? - Management indicated that they are closely monitoring market conditions and are implementing cost-control measures to manage potential increases in raw material prices [7][9] Question: What is the outlook for the copper smelting business? - The smelting business is expected to benefit from increased self-sufficiency as production from owned mines ramps up, which should enhance profitability [7][9]

Financial Data and Key Metrics Changes - The company achieved a total revenue of 1.6 billion yuan, representing a year-on-year growth of 12% [7] - Net profit reached 170 million yuan, showing a significant year-on-year increase of 200% [7] - Gross margin improved to 44.5% [7] - The company has over 2.9 billion yuan in cash and deposits, maintaining a dividend payout ratio of 80% and a dividend yield of approximately 8% [7][15] Business Line Data and Key Metrics Changes - The home cleaning product line is expected to grow by about 10% [2] - The pet business is viewed as a second growth curve, projected to account for 30% of total revenue in five years, with in-store revenue primarily from live pet sales [2][12] - The company maintains a leading position in the insecticide market for nine consecutive years, with a market share increase of 0.1-0.2% annually [19] Market Data and Key Metrics Changes - The company holds the second position in the home cleaning market, with a gap of about 10 percentage points from the market leader [4][6] - Online sales account for approximately 30% of total sales, with online growth slightly outpacing offline, although offline remains more profitable [8][21] Company Strategy and Development Direction - The company is pursuing a multi-category development strategy, focusing on enhancing market share in home cleaning products and expanding the pet product line [4][12] - Plans to open 100 new stores by the end of the year to strengthen market presence [11] - The company aims to reduce the proportion of insecticide sales to 40%, home cleaning to 30%, and pet products to 30% in the long term [12] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining market leadership and continuing to capture market share from smaller competitors [19] - The company anticipates further cost reductions of 1-2% due to ongoing supply chain reforms [18] - The focus will be on maintaining high-end product sales while ensuring stable growth across traditional and new products [15] Other Important Information - The company has successfully controlled costs through supply chain reforms, resulting in a 2.223% decrease in costs year-on-year and a 3.5 percentage point reduction in sales and management expense ratios [7][8] - The company is exploring investment and acquisition opportunities to enhance competitiveness in the consumer sector [8] Q&A Session Summary Question: What is the product structure for traditional incense and mosquito repellent products? - Management noted that traditional products still generate over 100 million yuan in sales annually, with slight growth observed [1] Question: What is the future strategy for home cleaning products? - The company aims to enhance market share and maintain a competitive edge through new product launches and channel expansion [5][24] Question: What are the main growth drivers for different business segments? - Growth will be driven by market share increases and stable growth in insecticide and home cleaning businesses, while the pet segment will expand through proprietary brands and store openings [12][16] Question: What are the pricing strategies for insecticide and mosquito repellent products? - The company offers a range of pricing from high to low-end products, targeting different consumer demographics [10][17] Question: Are there further cost reduction strategies in place? - A dedicated supply chain reform team is in place, with expectations for continued cost reductions [18] Question: What are the company's competitive advantages in the market? - The company holds the second position in home cleaning market share, with plans to enhance product offerings and expand channels [24]